Concord Medical Announces Share Repurchase Program BEIJING

Concord Medical Announces Share Repurchase Program

BEIJING, June 30, 2010 Concord Medical Services Holdings Limited ( Concord Medical or the

Company ) (NYSE: CCM), operator of the largest network of radiotherapy and diagnostic imaging

centers in China, today announced that its board of directors approved a share repurchase program,

effective immediately.

Under the program, Concord Medical is authorized to repurchase up to US$20 million worth of

outstanding American depositary shares ( ADSs ) from time to time depending on market conditions

and other factors as well as subject to relevant rules under United States securities regulations.

The share repurchase program will be funded with the Company s available working capital. As of

March 31, 2010, the Company had approximately 49.2 million ADSs outstanding and cash of

approximately RMB993.6 million, or $145.6 million1.

About Concord Medical

Concord Medical operates the largest network of radiotherapy and diagnostic imaging centers in

China in terms of revenues and the total number of centers in operation per available statistics.

The Company currently operates a network of more than 89 centers spanning 37 cities and 21

provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals

in China, the Company provides radiotherapy and diagnostic imaging equipments and manages the daily

operations of these centers located on its hospital partners premises. The Company also provides

ongoing training to doctors and other medical personnel in its network of centers to ensure a high

level of clinical care for patients.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute

forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of

1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995.

These forward-looking statements can be identified by terminology such as anticipate, believe,

estimate, expect, forecast, intend, may, plan, project, predict, should and

will and similar expressions. These forward looking statements are based upon management s

current views and expectations with respect to future events and are not a guarantee of future

performance. Furthermore, these statements are, by their nature, subject to a number of risks and

uncertainties that could cause actual performance and results to differ materially from those

discussed in the forward-looking statements as a result of a number of factors. Such factors

include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the

number of patients in existing centers; the establishment of specialty cancer hospitals; changes in

the healthcare industry in China, including changes in the healthcare policies and regulations of

the PRC government; and technological or

therapeutic changes affecting the field of cancer treatment and diagnostic imaging. Further

information regarding these and other risks is included in the Company s filings with the U.S.

Securities and Exchange Commission at www.sec.gov. The Company does not undertake any obligation to

update any forward-looking statement, except as required under applicable law.

For investor and media inquiries please contact:

Concord Medical Services

Brunswick Group, LLC

Brunswick Group, LLC